Actuate announces preclinical synergy for elraglusib with RAS inhibitors
Actuate Therapeutics said it announced new preclinical data showing synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Actuate announces preclinical combo synergy for elraglusib
Actuate said preclinical data show synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.